For decades, drugmakers have argued that patents are critical to bringing new drugs to the market. But in 2004, when a promising H.I.V. treatment emerged, Gilead Sciences decided to slow-walk its release to maximize profit on the company’s existing patents.
Rebecca Robbins, who covers the pharmaceutical industry for The Times, discusses one man’s case and how patents can create perverse incentives to delay new and better drugs.
Guest: Rebecca Robbins, a business reporter covering the pharmaceutical industry for The New York Times.
Background reading:
For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.
The Sunday Read: ‘Online Dating After 50 Can Be Miserable. But It’s Also Liberating.’
'The Interview': Vince Vaughn Turned This Interview Into Self-Help
The Secret Succession Fight That Will Determine the Future of Fox News
The Long Shadow of Julian Assange’s Conviction
An Escalating War in the Middle East
The V.P.’s Search for a V.P.
A Radical Reboot of Nuclear Energy
The Sunday Read: ‘The Kidnapping I Can’t Escape’
'The Interview': Pete Buttigieg Thinks the Trump Fever Could Break
Is One Third of Venezuela’s Population About to Flee?
The Harris Campaign Is Born
The Lingering Questions about the Attempt to Kill Trump
The New Hope, and New Worry, of Kamala Harris
Joe Biden Drops Out
Sunday Special: The 100 Best Books of the Century (So Far)
'The Interview': Joel Embiid Believes He Could Have Been the GOAT
At the Republican Convention, Trump Achieves Mythical Status
Trump 2.0: He’s Never Sounded Like This Before
The Surprise Ending to the Mar-a-Lago Documents Case
Trump Picks His Running Mate — and Political Heir
Create your
podcast in
minutes
It is Free
Up First
Consider This from NPR
Post Reports
The Ezra Klein Show
Global News Podcast